New Compounds Discovery and Development in Medicine — Advances in Research on Potential Therapeutic Agents and Drug Candidates, 2nd Edition

Topic Information

Dear Colleagues,

Despite huge progress in science and technology, we are still unable to cure many diseases. Research in recent years has shown that there is a great need for new, safe drugs in almost every field of medicine and pharmacy, including cardiology, neurology, oncology, microbiology, parasitology, virology, dermatology, hematology and endocrinology.

Therefore, the search for new compounds and substances of potential therapeutic importance is an important and urgent challenge for modern medicine. Publications of particular interest in our Special Topic include research and future perspectives on various compounds exhibiting a broad spectrum of biological activity (in vitro, in vivo and in silico studies). Research aimed at determining the molecular mechanisms of action of new compounds for their potential application in therapy will also be of interest. The search for new, active compounds is a tedious and lengthy process. The recent advances in research conducted towards the discovery of potential therapeutic agents and drug candidates, presented as part of this Special Topic, will provide the medical community with the latest knowledge in the field.

This Special Topic will publish original experimental research, reviews and preclinical observations regarding the discovery and development of new biologically active compounds in medicine.

Prof. Dr. Monika Wujec
Prof. Dr. Anna Bogucka-Kocka
Dr. Przemysław Kołodziej
Dr. Jacek Bogucki
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biomedicines biomedicines	3.9	5.2	2013	15.3 Days	CHF 2600	Submit
International Journal of Molecular Sciences ijms	4.9	8.1	2000	18.1 Days	CHF 2900	Submit
Medicines medicines	-	-	2014	24.5 Days	CHF 1400	Submit
Molecules molecules	4.2	7.4	1996	15.1 Days	CHF 2700	Submit
Pharmaceuticals pharmaceuticals	4.3	6.1	2004	12.8 Days	CHF 2900	Submit
Scientia Pharmaceutica scipharm	2.3	4.6	1930	31.4 Days	CHF 1000	Submit

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

1. Immediately share your ideas ahead of publication and establish your research priority;
2. Protect your idea from being stolen with this time-stamped preprint article;
3. Enhance the exposure and impact of your research;
4. Receive feedback from your peers in advance;
5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Related Topic

Published Papers (3 papers)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Biomedicines IJMS Medicines Molecules Pharmaceuticals Sci. Pharm.

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

13 pages, 3538 KiB  

Open AccessArticle

Natural Antioxidants from Acmella oleracea Extract as Dermatocosmetic Actives

by Claudia Maxim, Alexandra Cristina Blaga, Ramona Cimpoeșu, Inga Zinicovscaia, Alexandra Peshkova, Maricel Danu, Ana Simona Barna and Daniela Suteu

Sci. Pharm. 2024, 92(3), 52; https://doi.org/10.3390/scipharm92030052 - 19 Sep 2024

Viewed by 620

Abstract

Compounds from plant extracts make dermatocosmetic products more effective as they avoid the adaptation and resistance of the organism and achieve a synergistic effect of the molecular properties of interest. Acmella oleracea extract is considered to have great potential in preventing oxidative damage [...] Read more.

Compounds from plant extracts make dermatocosmetic products more effective as they avoid the adaptation and resistance of the organism and achieve a synergistic effect of the molecular properties of interest. Acmella oleracea extract is considered to have great potential in preventing oxidative damage and improving the appearance of the skin. The purpose of this article is to support the product formulated by preliminary studies of two types of O/W emulsions with 3% and 5% concentrations of Acmella oleracea extract. Physico-chemical methods were performed to evaluate the stability, microbiological control, rheological behavior and diffusion through the membrane. Good homogeneity, structural strength and flexibility, adequate skin diffusion, and high physico-chemical and microbiological stability were confirmed. The conclusions lead to the idea that these results require further in vivo studies as well as studies of toxicity and cytotoxicity to obtain the necessary data to place this product on the market. Full article

(This article belongs to the Topic New Compounds Discovery and Development in Medicine — Advances in Research on Potential Therapeutic Agents and Drug Candidates, 2nd Edition)

►▼ Show Figures

Figure 1

18 pages, 3172 KiB  

Open AccessArticle

Analgesic Effect of Human Placenta Hydrolysate on CFA-Induced Inflammatory Pain in Mice

by Keun-Tae Park, Heejoon Jo, So-Hyun Jeon, Kyeongsoo Jeong, Minju Im, Jae-Won Kim, Jong-Pil Jung, Hoe Chang Jung, Jae hun Lee and Woojin Kim

Pharmaceuticals 2024, 17(9), 1179; https://doi.org/10.3390/ph17091179 - 7 Sep 2024

Viewed by 526

Abstract

To evaluate the efficacy of human placenta hydrolysate (HPH) in a mice model of CFA-induced inflammatory pain. TNF-α, IL-1β, and IL-6 are key pro-inflammatory cytokine factors for relieving inflammatory pain. Therefore, this study investigates whether HPH suppresses CFA-induced pain and attenuates the inflammatory [...] Read more.

To evaluate the efficacy of human placenta hydrolysate (HPH) in a mice model of CFA-induced inflammatory pain. TNF-α, IL-1β, and IL-6 are key pro-inflammatory cytokine factors for relieving inflammatory pain. Therefore, this study investigates whether HPH suppresses CFA-induced pain and attenuates the inflammatory process by regulating cytokines. In addition, the relationship between neuropathic pain and HPH was established by staining GFAP and Iba-1 in mice spinal cord tissues. This study was conducted for a total of day 28, and inflammatory pain was induced in mice by injecting CFA into the right paw at day 0 and day 14, respectively. 100 μL of 20% glucose and polydeoxyribonucleotide (PDRN) and 100, 200, and 300 μL of HPH were administered intraperitoneally twice a week. In the CFA-induced group, cold and mechanical allodynia and pro-inflammatory cytokine factors in the spinal cord and plantar tissue were significantly increased. The five groups of drugs evenly reduced pain and gene expression of inflammatory factors, and particularly excellent effects were confirmed in the HPH 200 and 300 groups. Meanwhile, the expression of GFAP and Iba-1 in the spinal cord was increased by CFA administration but decreased by HPH administration, which was confirmed to suppress damage to peripheral ganglia. The present study suggests that HPH attenuates CFA-induced inflammatory pain through inhibition of pro-inflammatory cytokine factors and protection of peripheral nerves. Full article

(This article belongs to the Topic New Compounds Discovery and Development in Medicine — Advances in Research on Potential Therapeutic Agents and Drug Candidates, 2nd Edition)

►▼ Show Figures

Figure 1

15 pages, 5451 KiB  

Open AccessArticle

Methylene Blue Reduces Electroretinogram Distortion and Ganglion Cell Death in a Rat Model of Glaucoma

by Ronan Nakamura, Nicolás S. Ciranna, Juan C. Fernández, Rafael Peláez, Álvaro Pérez-Sala, Miriam Bobadilla, Juan J. López-Costa, César F. Loidl, Alfredo Martínez and Manuel Rey-Funes

Biomedicines 2024, 12(9), 1983; https://doi.org/10.3390/biomedicines12091983 - 2 Sep 2024

Viewed by 576

Abstract

Glaucoma is the second leading cause of blindness worldwide and is, in most cases, a consequence of elevated intraocular pressure (IOP), ultimately resulting in the death of retinal ganglion cells (RGCs). Current treatments are mostly focused on normalizing IOP, but we propose the [...] Read more.

Glaucoma is the second leading cause of blindness worldwide and is, in most cases, a consequence of elevated intraocular pressure (IOP), ultimately resulting in the death of retinal ganglion cells (RGCs). Current treatments are mostly focused on normalizing IOP, but we propose the additional use of neuroprotective agents, including methylene blue (MB), to block the loss of RGCs. Wistar rats were subjected to episcleral vein cauterization (EVC) in the left eye while the right eye was sham-operated. One week later, they were divided into two groups, which were injected with either 2.0 mg/kg MB or phosphate-buffered saline (PBS), twice a day, for 7 days. Fifteen days after surgery, rats were tested with scotopic electroretinography (ERG) or pattern electroretinography (PERG). After sacrifice, the number of RGCs and the thickness of the inner retina (IR) were evaluated both in the peripheral and central areas of the retina. Scotopic ERG showed a marked reduction (p < 0.0001) on the a- and b-wave amplitude and oscillatory potential (OP) complexity of the eyes subjected to EVC. These parameters were significantly (p < 0.01) restored by the application of MB. PERG indicated that EVC was responsible for a very significant decrease in N2 amplitude (p < 0.0001) and prolongation of N2 implicit time (p < 0.0001). Treatment with MB significantly restored N2 amplitude (p < 0.0001). In parallel with the ERG results, morphological analysis showed a significant loss of RGCs (p < 0.0001) and IR thickness (p < 0.0001) in both the peripheral and central retinas subjected to EVC, which was significantly prevented (p < 0.0001) by MB treatment. We have shown that MB treatment can be effective in preventing physiological and morphological hallmarks of optic neuropathy in a model of ocular hypertension, which faithfully recapitulates human open-angle glaucoma. Due to its high safety profile, this drug could therefore represent a new pharmacologic strategy to prevent vision loss in glaucoma patients. Full article

(This article belongs to the Topic New Compounds Discovery and Development in Medicine — Advances in Research on Potential Therapeutic Agents and Drug Candidates, 2nd Edition)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-3